Hong Kong Skyline
Nicada | E+ | Getty Images
Regencell Bioscience HoldingsEarly Hong Kong-based Bioscience Company, with no income, is the latest speculative foreign stock to attract an extraordinary surge in trading demand.
Regencell’s shares say it is developing traditional Chinese herbal treatments to treat childhood attention deficit hyperactivity disorder and autism more than three times as much as Monday after a 38-1 split was declared on June 2. By the end of Monday, Regencell, which was founded in 2014 and traded on Nasdaq under the ticker “RGC” since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.
Stock continued to bounce Tuesday, earning over 25%. The company’s annual annual performance also went off the charts, rising more than 58,000% in 2025. Currently, the market value is Topslulemon, eBay and Kraft Heinz, which has a $36 billion market value. The shares have been traded with Penny at one point in the past year.
Recencell Bioscience Holdings in 2025.
Regencell is the latest example of speculative international stocks that are attracting attention during summer trading. For example, August 2022, AMTD DigitalHong Kong-based fintech company rose 126%, temporarily giving a greater market value coca cola and Bank of America.
Earlier this month, Regencell described a stock split that was designed solely to “enhance liquidity in the market for the company’s common stock and make it more accessible to investors.” A stock split changes nothing fundamentally about the company.
The Regencell surge came into the spotlight even after Robert F. Kennedy Jr. was sworn in February as U.S. Department of Health and Human Services secretary, and focused on alternative medicines. Kennedy, a vaccine skeptic, took steps last week to discourage the U.S. from routine immunizations and removed all members of the panel advising the Centers for Disease Control and Prevention for Vaccines.
Regencell stocks often make huge swings for the day. For example, the stock rose about 30% on March 21, then fell 30% on the next trading day.
Unclear treatment, zero profit
Despite wild spikes in stock, little is known about the effectiveness and commercialization of Regencell’s treatment for ADHD and autism spectrum disorders.
Regencell’s business focuses on its own traditional Chinese herbal medicine (TCM), developed in partnership with TCM practitioner Sik-kee Au, using “Sik-kee au tcm brain theory.” Sik-Kee Au is the father of Regencell CEO Yat-Gai Au, the company said in a 2022 statement.
According to FactSet data, CEOs control 86.24% of the total number of shares outstanding.
Three liquid-based oral take TCM formula candidates deal with mild, moderate and severe conditions and claim to contain only natural ingredients such as so-called “detoxifying herbs,” blood circulation herbs and digestive herbs.
“These TCM formulas form the basis for TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD,” reads the Regencell website.
In his latest annual report, filed last October, Regencell said he also submitted TCM-style regulatory approval. According to SEC filings, for the fiscal years ended June 2024 and June 2023, Regencell incurred total losses of $4.36 million and $6.06 million, respectively.
Read the submissions: “You may not generate revenue from TCM Formula candidates, apply for regulatory approval, or receive distribution capabilities or experience, or granted or pending patent applications and may not be beneficial.”
Regencell has not responded to CNBC requests for comments.
Regencell’s latest patient case study dated November 15, 2023 said 28 patients were treated for three months in their second efficacy trial, showing improvements in ADHD and ASD symptoms, according to the company’s website.
In previous cases, Regencell said in a 2021 news release that it used the AU’s revised, unique cold and flu TCM formula to treat suspected or confirmed COVID-19 cases. According to the statement, the covid terms were called improvements, and in September 2021, it formed a joint venture with Honor Epic Enterprises Limited, which began commercializing the company’s community treatment in countries belonging to the Association of Southeast Asian Countries.
Online buzz
The stock has attracted mostly chatter on social media over the past few years. These comments made suggest both retailer enthusiasm and skepticism.
One user on Reddit page “R/ShortSqueeze” wrote on Monday that Regencell “trades like Meme Coin.” Another user said in a post made three months ago, “I take my scalp every day to make a little profit from RGC.” The stock price jumped 1,360% in May alone.
On LinkedIn in May, an investor said, “I can’t stop laughing,” after reading the company’s description. According to his profile, another post from a user in the pharmaceutical industry said last week that Regencell became “stock to see” after a spike in “no official news or catalysts.” Another LinkedIn user commented on Regencell last month, saying, “China-based, low volume and no official news, Bizarro.”
On X, one user wrote in a Monday post, “We will nominate Regencell for #completebullsh___companyoftheyear.”
– CNBC’s Scott Schnipper contributed the report.
